DeutschNewstral
Article
bizjournals.com on 2021-01-19 23:54
Seattle biotech AltPep closes $23M funding round for Alzheimer’s research
Related news
- Seattle biotech company RareCyte closes $22M funding roundbizjournals.com
Seattle biotech firm scores $85 million for work on Alzheimer’s drug, despite hurdles of coronavirus pandemicSeattle Times- Boulder biotech acquires Seattle companybizjournals.com
Amazon providing $23M for affordable housing in Seattlekentucky.com- Amazon to commit $23M for affordable housing projects in Seattlebizjournals.com
- Seattle biotech expands portfolio with Boston acquisitionbizjournals.com
- Seattle biotech Oncothyreon names new CEObizjournals.com
- Seattle biotech outpaces Washington's public companiesbizjournals.com
Seattle biotech PhaseRx files to go publicseattletimes.com- Seattle Genetics buys biotech factory in Bothellseattletimes.com
- Former Zillow CFO heads to Seattle biotechbizjournals.com
- Seattle biotech Silverback Therapeutics prices upsized IPOseattletimes.com
- Seattle biotech Faraday Pharmaceuticals names new CEObizjournals.com
- Seattle biotech Adaptive buys San Francisco firmseattletimes.com
- Seattle Genetics operations chief resigns to lead stealthy Seattle biotechbizjournals.com
UK biotech group raises £48mn for Alzheimer’s researchFinancial Times- WA participants sought for ongoing research on new Alzheimer’s drugseattletimes.com
- Funding Alzheimer’s research is as critical as fighting the stigmaseattletimes.com
- Seattle small businesses, neighborhoods to get $23M in aid under mayor’s recovery planSeattle Times